HEPCDAC Indication: Daclatasvir is used with another antiviral drug (sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Daclatasvir should not be used without sofosbuvir. Daclatasvir and sofosbuvir can be used with another antiviral medicine (ribavirin). HEPCDAC drugs together reduce the amount of hepatitis C virus in your body that helps the immune system fight the infection and can help the liver recover.
Chronic hepatitis C can cause serious liver problems such as scarring (cirrhosis) or liver cancer. Posology and method of administration: HEPCDACdaclatasvir exactly as a health care provider says. Do not change the dose if your healthcare provider says it. Do not stop taking daclatasvir without first talking to your healthcare provider. Take 1 hour each day with or without food. The recommended use of daclatasvir for the treatment of chronic hepatitis C infection is 60 mg orally, once daily, with or without food, in combination with sofosbuvir. The recommended duration of treatment is 12 weeks.
Disclaimer : This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.